potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.
|
6. A pharmaceutical formulation comprising, in a pharmaceutically acceptable carrier, a tumor inhibiting amount of an antineoplastic agent and a potentiating agent in an amount effective to enhance the efficacy of said antineoplastic agent, said potentiating agent selected from the class consisting of ##STR3## wherein R is C1-4 alkyl, and the pharmaceutically acceptable salts thereof.
1. A method of increasing the sensitivity of a tumor to an antineoplastic agent, which tumor is harbored in a subject and which tumor is resistant to said antineoplastic agent, comprising concurrently administering to said subject an antineoplastic agent and a potentiating agent, said potentiating agent selected from the class consisting of ##STR2## wherein R is C1-4 alkyl, and the pharmaceutically acceptable salts thereof, said potentiating agent being administered in an amount effective to increase the sensitivity of said tumor to said antineoplastic agent.
2. A method according to
3. A method according to
5. A method according to
7. A pharmaceutical formulation as claimed in
|
|||||||||||||||||||||||||||||||||||
This application is a division of pending application Ser. No. 07/539,836, filed Jun. 18, 1990 and now U.S. Pat. No. 5,124,330.
The present invention relates to the use of pyridine derivatives such as acrivastine ethyl ester as adjuvant chemotherapy for neoplasias resistant to multiple drugs. The present invention also relates to the use of such compounds as an agent for enhancing the therapeutic effect of multiple antitumor agents.
Complete cures of various tumors like leukemias, lymphomas and solid tumors by the use of chemotherapeutic agents are rare because of heterogeneous sensitivity of tumor cells to each antitumor agent. Cancer chemotherapy also fails because of intrinsic resistance of tumors to multiple drug therapies. In other cases, a tumor may become resistant to the antitumor agents used in a previous treatment. The therapeutic effects of these agents are then eliminated. An even graver problem is that recurrent cancers are resistant not only to the cancer suppressants used in previous treatments, but also manifest resistance to other antitumor agents, unrelated to the agent used previously either by chemical structure or by mechanism of action. These phenomena are collectively referred to as multiple drug resistance (mdr) and contribute widely to cancer treatment failures in the clinic.
The major documented cause of multiple drug resistance is overexpression of a membrane glycoprotein (the multiple drug transporter) responsible for pumping structurally diverse antitumor drugs from cells. See D. Houseman et al., A Molecular Genetic Approach to the Problem of Drug Resistance in Chemotherapy, 504-517 (1987) (Academic Press, Inc.); R. Fine and B. Chabner, Multidrug Resistance, in Cancer Chemotherapy 8, 117-128 (H. Pinedo and B. Chabner eds. 1986).
Tumor cells expressing elevated levels of the multiple drug transporter accumulate far less antitumor agents intracellularly than tumor cells having low levels of this enzyme. The degree of resistance of certain tumor cells has been documented to correlate with both elevated expression of the drug transporter and reduced accumulation of antitumor drugs. See M. Gottesman and I. Pastan, J. Biol. Chem. 263, 12163 (1988); see also A Fojo et al., Cancer Res. 45, 3002 (1985). This form of multiple drug cross-resistance involves agents derived from natural products, such as the vinca alkaloids, the anthracyclines, the epipodophyllotoxins, actinomycin D and plicamycin. See I. Pastan and M. Gottesman, New England J. Med. 1388, 1389 Table 1 (May 28, 1987).
Adenocarcinomas derived from adrenal, kidney, liver, small intestine, and colon tissue are notorious for exhibiting inherent cross-resistance to chemically unrelated chemotherapeutic agents. See M. Gottesman and I. Pastan, supra at 12165; see also A. Fojo et al., J. Clin. Oncol. 5, 1922 (1987). These tissues normally express higher levels of the multidrug transporter. Other tumors documented to express high levels of the multidrug transporter include pancreatic, carcinoid, chronic myelogenous leukemia in blast crisis, and non-small cell lung carcinoma. Tumors documented to initially be drug-sensitive but to then become drug resistant include neuroblastoma, pheochromocytoma, acute lymphocytic leukemia in adults, acute nonlymphocytic leukemia in adults, nodular poorly differentiated lymphoma, breast cancer and ovarian cancers. It is estimated by the National Cancer Institute that approximately half a million tumor samples a year will be drug resistant because of aberrant levels of expression of the multidrug transporter. See L. Goldstein et al., Expression of Multidrug Resistance Gene in Human Cancers, J. National Cancer Institute 81, 116 (1988).
Elevated levels of expression of the mdr drug transporter in these tumors would lead to reduced intracellular levels of antitumor agents in the tumor and would cause suppression of chemotherapeutic efficacy. Tumors having elevated levels of the multiple drug transporter would require therapeutic doses of cancer suppressants far in excess of tumors exhibiting lower levels of the mdr drug transporter. Agents that inhibit the active efflux of antitumor agents by the drug transporter or agents that potentiate the efficacy of chemotherapeutic agents would enhance the activity of various antitumor agents on tumor cells. As a result of the present inventor's study, it has unexpectedly been found that when the agents disclosed herein are used together with an antitumor agent, they enhance the therapeutic effect of the antitumor agent.
A number of agents used clinically as calcium channel-blockers, calmodulin inhibitors and antiarrhythmic agents promote the activity of antitumor agents against resistant tumor cells, see Tsuruo et al., Cancer Res. 44, 4303 (1984); 43, 2267 (1983). Verapamil, caroverine, clomipramine, trifluoperazine, prenylamine, diltiazem, nicardipine, and quinidine enhance the activity of antitumor agents against resistant sublines of murine leukemia cells. Most agents potentiating the activity of antitumor agents are calcium antagonists, and the serious cardiotoxicities that arise during treatment have limited their clinical usefulness. While the inventor does not wish to be bound by any theory of operation for the present invention, it is noted that the agents disclosed herein are not known to have calcium antagonism. They have, however, been found to elevate the intracellular concentration of antineoplastic drugs in tumor cells overexpressing the multiple drug transporter. Sensitization of drug resistant tumors and elevation of intracellular antitumor drug concentrations probably occur by a mechanism different from calcium antagonism.
An object of the present invention is to provide an agent for enhancing the therapeutic effect of an antineoplastic agent by administering to a subject harboring a tumor a compound of Formula (I) below or a pharmaceutically acceptable salt thereof (hereafter referred to as the "potentiating agent"). ##STR1## wherein R is C1-4 alkyl (e.g., methyl, ethyl, isopropyl, or butyl).
An aspect of the present invention is a method of increasing the sensitivity of a tumor to an antineoplastic agent when the tumor is resistant to the antineoplastic agent by administering to the subject harboring the resistant tumor a potentiating agent concurrently with an antineoplastic agent. Resistance to the antineoplastic agent may (a) be an intrinsic property of the tumor or (b) develop in response to prior treatment with the same antineoplastic agent or another antineoplastic agent capable of selecting for multi-drug resistance.
Another aspect of the present invention is a method of selectively inhibiting the growth of tumor cells in a subject in need of such treatment by concurrently administering to the subject an antineoplastic agent and a potentiating agent. The potentiating agent is administered in an amount effective to (a) reduce the amount of the antineoplastic agent required to achieve the same growth inhibiting effect on the tumor cells by the antineoplastic agent achieved without the concurrent administration of the potentiating agent; or (b) inhibit the development of multiple drug resistance in the tumor cells after treatment with the antineoplastic agent over time.
Another aspect of the present invention is a method of inhibiting multiple drug resistance in a subject in need of such treatment by administering the subject a potentiating agent in an amount effective to combat multiple drug resistance.
Another aspect of the present invention is the use of a potentiating agent as disclosed herein for the manufacture of a medicament for the inhibition of multiple drug resistance in tumors.
Another aspect of the present invention is a pharmaceutical formulation containing a potentiating agent as disclosed herein in combination with an antineoplastic agent in a pharmaceutically acceptable carrier.
Potentiating agents disclosed herein include:
(A) (E)-3-{6-[3-Pyrrolidino-1-(4-tolyl)prop-1E-enyl]-2-pyridol}acrylic acid; and
(B) Ethyl (E)-3-{6-[3-pyrrolidino-1-(4-tolyl)prop-1E-enyl]-2-pyridyl}acrylate.
Compound (B) is exemplary of the present invention.
The synthesis of Compound (A) is given in U.S. Pat. No. 4,650,807 to Findlay and Coker. Compound (B) is an ester of Compound (A) and may be prepared by known techniques.
A preferred category of multiple drug resistant tumor cells to be treated by the method of the present invention are multiple drug resistant cells characterized by the multidrug transporter--mediated pumping of antineoplastic agents out of the tumor cells. The multidrug transporter protein is described in M. Gottesman and I. Pastan, supra. Thus, tumor cells treated by the present invention are preferably those characterized by (a) the expression of the multidrug transporter protein at high levels, or (b) the ability to express the multidrug transporter protein upon selection by an antineoplastic agent.
Exemplary of tumor cells which express the multidrug transporter at high levels (intrinsically resistant cells) are adenocarcinoma cells, pancreatic tumor cells, carcinoid tumor cells, chronic myelogenous leukemia cells in blast crisis, and non-small cell lung carcinoma cells.
Exemplary of tumor cells having the ability to express the multidrug transporter protein upon selection by an antineoplastic agent are neuroblastoma cells, pheochromocytoma cells, adult acute lymphocytic leukemia cells, adult acute nonlymphocytic leukemia cells, nodular poorly differentiated lymphoma cells, breast cancer cells and ovarian cancer cells.
A preferred group of tumor cells for treatment in the present invention are the adenocarcinomas, including adenocarcinomas of adrenal, kidney, liver, small intestine and colon tissue, with kidney adenocarcinoma cells particularly preferred.
Preferred antineoplastic agents for use in the present invention are those to which multidrug transporter-mediated multiple drug resistant cells develop resistance. Exemplary of such antineoplastic agents are vinca alkaloids, epipodophyllotoxins, anthracycline antibiotics, actinomycin D, plicamycin, puromycin, gramicidin D, taxol, colchicine, cytochalasin B, emetine, maytansine, and amsacrine (or "mAMSA"). Preferred are vinca alkaloids, epipodophyllotoxins, anthracyclene antibiotics, actinomycin D, and plicamycin.
The vinca alkaloid class is described in Goodman and Gilman's The Pharmacolooical Basis of Therapeutics, 1277-1280 (7th ed. 1985) (hereafter "Goodman and Gilman"). Exemplary of vinca alkaloids are vincristine, vinblastine, and vindesine.
The epipodophyllotoxin class is described in Goodman and Gilman, supra at 1280-1281. Exemplary of epipodophyllotoxins are etoposide, etoposide orthoquinone, and teniposide.
The anthracycline antibiotic class is described in Goodman and Gilman, supra at 1283-1285. Exemplary of anthracycline antibiotics are daunorubicin, doxorubicin, mitoxantraone, and bisanthrene. Daunorubicin and doxorubicin are preferred.
Actinomycin D, also called Dactinomycin, is described in Goodman and Gilman, supra at 1281-1283. Plicamycin, also called mithramycin, is described in Goodman and Gilman, supra at 1287-1288.
The phrase "concurrently administering," as used herein, means that the antineoplastic agent and the potentiating agent are administered either (a) simultaneously in time (optionally by formulating the two together in a common carrier), or (b) at different times during the course of a common treatment schedule. In the latter case, the two compounds are administered at times sufficiently close for the potentiating agent to enhance the selective growth-inhibiting action of the antineoplastic agent on the tumor cells.
Subjects to be treated by the method of the present invention include both human and animal (e.g., dog, cat, cow, horse) subjects, and are preferably mammalian subjects.
The potentiating agent is administered in an amount effective to enhance the efficacy of the antineoplastic agent. The potentiating agent is preferably administered in a total amount per day of not more than about 50 mg/kg body weight, more preferably not more than about 25 mg/kg, and most preferably not more than about 5 mg/kg. With respect to minimum dose, the potentiating agent is preferably administered in a total amount per day of at least about 0.01 mg/kg, more preferably at least about 0.1 mg/kg, and most preferably at least about 1 mg/kg. The potentiating agent may be administered once or several times a day.
As noted above, the compounds of Formula (I) may be administered per se or in the form of a pharmaceutically acceptable salt. When used in medicine, the salts of the compound of Formula (I) should be both pharmacologically and pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare the free active compound or pharmaceutically acceptable salts thereof and are not excluded from the scope of this invention. Such pharmacologically and pharmaceutically acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluenesulfonic, tartaric, citric, isethionic, methanesulphonic, formic, malonic, succinic, naphthalene-2-sulphonic and benzenesulphonic. Also, pharmaceutically acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group. Thus, the present invention also provides pharmaceutical formulations, both for veterinary and for human medical use, which comprise the potentiating agent together with one or more pharmaceutically acceptable carriers thereof and optionally any other therapeutic ingredients. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.
Pharmaceutical formulations of the present invention may optionally include an antineoplastic agent, preferably an agent as described above. Such a formulation is useful for concurrently administering an antineoplastic agent and the potentiating agent in a method as described above.
The formulations include those suitable for oral, rectal, topical, nasal, ophthalmic or parenteral (including subcutaneous, intramuscular and intravenous) administration. Formulations suitable for oral and parenteral administration are preferred.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into desired formulations.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the potentiating agent as a powder or granules; or a suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, with the active compound being in a free-flowing form such as a powder or granules which is optionally mixed with a binder, disintegrant, lubricant, inert diluent, surface active agent or dispersing agent. Molded tablets comprised of a mixture of the powdered active compound with a suitable carrier may be made by molding in a suitable machine.
A syrup may be made by adding the active compound to a concentrated aqueous solution of a sugar, for example sucrose to which may also be added any accessory ingredient(s). Such accessory ingredient(s) may include flavorings, suitable preservatives, an agent to retard crystallization of the sugar, and an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol.
Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound, which is preferably isotonic with the blood of the recipient.
Nasal spray formulations comprise purified aqueous solutions of the active compound with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucous membranes.
Formulations for rectal administration may be presented as a suppository with a suitable carrier such as cocoa butter, or hydrogenated fats or hydrogenated fatty carboxylic acids.
Ophthalmic formulations are prepared by a similar method to the nasal spray, except that the pH and isotonic factors are preferably adjusted to match that of the eye.
Topical formulations comprise the active compound dissolved or suspended in one or more media such as mineral oil, petroleum, polyhydroxy alcohols or other bases used for topical pharmaceutical formulations. The addition of other accessory ingredients, vide infra, may be desirable.
In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavoring agents, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
The following Examples are provided to illustrate the present invention, and should not be construed as limiting thereof. Temperatures are given in degrees Celsius unless otherwise indicated.
PAC In Vitro Cytotoxicity of Potentiating Agents in Chinese Hamster Ovary CellsChinese hamster ovary (CHO) tissue culture cells were obtained from Dr. Vic Ling, Princess Margaret Hospital, Toronto, Canada. The parental cell line (AuxB1) and a multidrug resistant line (C5S32) having an amplified form of the MDR drug transport protein were plated into 96-well microtitre culture dishes at 250 or 500 cells per well in minimal essential medium, type alpha, 10% fetal calf serum and incubated in 95% oxygen/5% carbon dioxide for 48 hours. After this period, the medium was changed and one-half of the culture was treated with Actinomycin D (Act D) (0.01 μM for AuxB1 cells and 0.5 μM for C5S32 cells). C5S32 cells are about 200-fold resistant to Actinomycin D compared to the parental AuxB1 cell line. In addition to Act D some of the cultures also received a dose of the potentiating agent at 1 and 10 μM. Thus, four conditions were tested in each screening assay: untreated cells in medium alone, cells receiving Act D alone, cells incubated with the potentiating agent alone, and cells incubated with a combination of Act D and the potentiating agent. Both the parental and mdr cell lines were treated with these four conditions simultaneously. Each experimental condition reported below is based on the average absorbance from eight replicate samples. The incubation with Act D and the test drug continued for 96 additional hours, after which 0.5 mg/ml MTT dye was added to the cultures and allowed to incubate for three hours. The cells were solubilized by addition of DMSO and the absorbance at 570 nm was monitored. The absorbance is directly related to the number of surviving cells in the culture dish.
In Table 1 below, the absorbance was normalized so that cytotoxicity of the potentiating agent could be evaluated. Untreated cultures were given a value of 1.00 and the cultures receiving 1 and 10 μM of the potentiating agent are reported as a fraction of this value. To evaluate the compounds for inducing synergism with Actinomycin D, the absorbance values of cultures receiving Act D alone were assigned a value of 1.00 and cultures receiving the combination of Act D and potentiating agent Act D are reported as a fraction of this control. In most experiments, this concentration of Act D gave a reduction in cell number 10-20% below the value of completely untreated cultures.
| TABLE 1 |
| ______________________________________ |
| In Vitro Cytotoxicity of Potentiating |
| Agents in Chinese Hamster Ovary Cells |
| Wildtype Drug Resistant |
| AUXB1 C5S32 |
| Compound |
| Dose 0 +ACT D 0 +ACT D |
| ______________________________________ |
| (A) 1 μM 1.00 0.95 0.90 0.62 |
| 10 μM 1.00 0.85 0.70 0.60 |
| (B) 1 μM 0.92 0.63 0.77 0.63 |
| 10 μM 0.93 0.29 0.52 0.14 |
| ______________________________________ |
The procedure for assaying the cytotoxicity of potentiating agents with human KB epidermoid carcinoma cells is essentially the same as the assay procedure described above for use with Chinese hamster ovary cells. In brief, KB 3-1 (wt) and KB V-1 (mdr) cells are plated at 500 cells/well in 96-well culture plates in Dulbecco's modified eagle medium, supplemented with 10% fetal calf serum. After 48 hours of incubation at 37°C, the media is changed and cells are treated with actinomycin D at 0.1 nM (3-1) or 20 nM (V-1). The test potentiating agent is introduced to one-half the untreated cultures and one-half the Act D treated cultures at 1 and 10 μM. After 96 hours of additional incubation at 37°C, 0.5 mg/ml MTT dye is added, the cells are incubated for three hours, after which the cells are dissolved in DMSO, and the absorbance is then read at 570 nm. The data is given in Table 2 below.
| TABLE 2 |
| ______________________________________ |
| In Vitro Cytotoxicity of Potentiating Agents |
| in Human KB Epidermoid Carcinoma Cells |
| Wildtype Drug Resistant |
| KB 3-1 KBV-1 |
| Compound |
| Dose 0 +ACT D 0 +ACT D |
| ______________________________________ |
| (A) 1 μM 0.98 0.92 0.68 0.72 |
| 10 μM 1.00 0.95 0.66 0.77 |
| (B) 1 μM 0.58 0.55 0.36 0.48 |
| 10 μM 0.37 0.45 0.14 0.04 |
| ______________________________________ |
Acrivastine (2.00 g, 5.74 mmol) was dissolved in n-butanol (200 mL) with 0.63 g of conc. sulfuric acid and heated to reflux under nitrogen for 72 hours. The reaction was cooled to room temperature and neutralized with addition of saturated aqueous sodium bicarbonate. The solvent was removed under vacuum and the residue diluted wlth 50 mL of diethyl ether, washed with 30 mL of water followed by saturated aqueous sodium chloride, and dried over sodium sulfate. The solvent was removed under vacuum and the residue was purified by chromatography on silica gel with 0-1% methanol in dichloromethane as eluent to give a dark oil. The hydrochloride salt was prepared by dissolving the oil in ethanol and adding 0.2 M ethanolic hydrogen chloride to pH=4.5. Addition of diethyl ether and chilling the solution gave 0.380 g (15%) of light brown crystals (m.p. 119.5°-121°C). Calc. for C26 H32 N2 O2 ·HCl·0.25 H2 O: C,70.10; H,7.58; N, 6.29, Cl,7.96. Found: C,70.12; H,7.60; N,6.39, Cl,7.89. NMR (amine form, CDCl3, 200 MHz, ppm downfield from TMS): 0.97 (t,3H,J=7), 1.45 (sextet,2H,J=7), 1.77 (brd s (4H) over quintet (2H,J=7)), 2.40 (s,3H), 2.52 (brd s,4H), 3.19 (d,2H,J=7), 4.22 (t,2H,J=7), 6.82 (d,1H,J=8), 7.04 (d,1H,J=15.6), 7.08 (d,2H,J=8), 7.15-7.25 (mult,4H), 7.50 (t,1H,J=8), 7.66 (d,1H,J=15.6).
PAC (E)-Isopropyl 3-(6-(E)-3-(1-pyrrolidinyl-1-(4-tolyl)-1-propenyl)-2-pyridyl)acrylateAcrivastine (1.01 g, 2.90 mmol) was dissolved in 50 mL of isopropyl alcohol with 0.67 g of conc. sulfuric acid and heated to reflux under nitrogen for 28 hours. The reaction was cooled to room temperature, diluted with 50 mL of diethyl ether, washed with two 30 mL portions of 1.0 M aqueous sodium hydroxide followed by saturated aqueous sodium chloride, and dried over sodium sulfate. The solvent was removed under vacuum and the residue was purified by chromatography on silica gel with 0-1% methanol in dichloromethane as eluent to give 0.57 g of dark oil which crystallized upon cooling. The product was recrystallized from acetonitrile to give 220 mg (19%) of beige crystals (m.p. 88°-89°C), Calc. for C25 H30 N2 O2 : C,76.89; H,7.74; N,7.17. Found: C,76.72; H,7.81; N,7.08. NMR (CDCl3, 200 MHz, ppm downfield from TMS): 1.32 (d,6H,J=6.2), 1.78 (shrp mult,4H), 2.40 (s,3H), 2.55 (shrp mult,4H), 3.21 (d,2H,J=7.0), 5.15 (septet,1H,J=6.2), 6.82 (d,1H,J=7.2), 7.02 (d,1H,J=15.6), 7.09 (d,2H,J=8), 7.15-7.25 (mult,4H), 7.50 (t,1H,J=7.8), 7.65 (d,1H,J=15.6).
PAC FormulationsIn the formulations of this Example the active compound is a compound of Formula (I) described hereinbefore.
| ______________________________________ |
| (A) - Injectable |
| Amount Per |
| Ingredient Ampoule |
| ______________________________________ |
| Active Compound 1.0 mg |
| Water for Injections, q.s. |
| 1.0 mL |
| ______________________________________ |
The finely ground active compound is dissolved in the water for injections. The solution is filtered and sterilized by autoclaving.
| ______________________________________ |
| (B) - Syrup |
| Amount Per |
| Ingredient Ampoule |
| ______________________________________ |
| Active Compound 1.0 mg |
| Ethanol 0.3 mg |
| Sucrose 2.0 mg |
| Methylparaben 0.5 mg |
| Sodium Benzoate 0.5 mg |
| Cherry Flavour q.s. |
| Colouring q.s. |
| Water Q.S. to 5.0 mL |
| ______________________________________ |
Ethanol, sucrose, sodium benzoate, methylparaben, and flavouring are combined in 70% of the total batch quantity of water. Colouring and the active compound are dissolved in the remaining water, then the two solutions are mixed and clarified by filtration.
| ______________________________________ |
| (C) - Tablet |
| Amount Per |
| Ingredient Tablet |
| ______________________________________ |
| Active Compound 1.0 mg |
| Lactose 110.0 mg |
| Corn Starch, 2.5 mg |
| Pregelatinized |
| Potato Starch 12.0 mg |
| Magnesium stearate |
| 0.5 mg |
| ______________________________________ |
The active compound is finely ground and intimately mixed with the powdered excipients lactose, corn starch, potato starch and magnesium stearate. The formulation is then compressed to afford a tablet weighing 126 mg.
| ______________________________________ |
| (D) - Capsule |
| Amount Per |
| Ingredient Capsule |
| ______________________________________ |
| Active Compound 1.0 mg |
| Lactose 440.0 mg |
| Magnesium Stearate |
| 5.0 mg |
| ______________________________________ |
The finely ground active compound is mixed with the powdered excipients lactose and magnesium stearate and packed into gelatin capsules.
| ______________________________________ |
| (E) - Nasal Spray |
| Amount Per |
| Ingredient 100.0 mL |
| ______________________________________ |
| Active Compound 1 g |
| Sodium Chloride 0.8 g |
| Preservative 0.5 g |
| Purified Water 100.0 mL |
| ______________________________________ |
The preservative is dissolved in warm purified water and after cooling to 25°-30°C the sodium chloride and active compound are added. The pH is then adjusted to 5.5-6.5 and purified water is added to bring the final volume to 100.0 mL.
The foregoing examples are illustrative of the present invention, and are not to be taken as restrictive thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 3497596, | |||
| 3993757, | Jun 06 1975 | Richardson-Merrell Inc. | Method of treating inflammation with morphanthridines |
| 3996222, | Feb 01 1972 | CRC Compagnia de Ricerca Chimica | Piperazine derivatives |
| 4562258, | Feb 04 1982 | BURROUGHS WELLCOME CO | 6-[3-Amino-1-(4-tolyl)prop-1E-enyl]pyridine-2-carboxylic acid derivatives having antihistaminic activity |
| 4628047, | May 28 1982 | JAPANESE FOUNDATION FOR CANCER RESEARCH; Tanabe Seiyaku Co., Ltd. | Agent for enhancing antitumor activity of antitumor agent |
| 4650807, | Feb 04 1982 | MEDEVA CALIFORNIA, INC | Antihistaminic compositions and methods containing pyridine derivatives |
| 4657918, | Feb 04 1982 | Burroughs Wellcome Co. | 3-[6-[3-pyrrolidino-1-(4-tolyl)prop-1e-enyl]-2-pyridyl]propionic acid and derivatives having anti-histaminic activity |
| 4690933, | Jul 27 1984 | WELLCOME FOUNDATION LIMITED, THE; BURROUGHS WELLCOME CO | Pyridylvinyl-1H tetrazole having antihistamine activity |
| CH407990, | |||
| CH419172, | |||
| DE1493451, | |||
| DE1909408, | |||
| DE3410848A1, | |||
| EP85959, | |||
| EP133323, | |||
| EP135087, | |||
| EP187700, | |||
| EP214779, | |||
| EP270926, | |||
| EP353692, | |||
| EP361485, | |||
| EP351887, | |||
| FR4016, | |||
| GB1018985, | |||
| GB2120941, | |||
| JP6185320, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jun 10 1992 | Burroughs Wellcome Company | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Mar 02 1996 | 4 years fee payment window open |
| Sep 02 1996 | 6 months grace period start (w surcharge) |
| Mar 02 1997 | patent expiry (for year 4) |
| Mar 02 1999 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Mar 02 2000 | 8 years fee payment window open |
| Sep 02 2000 | 6 months grace period start (w surcharge) |
| Mar 02 2001 | patent expiry (for year 8) |
| Mar 02 2003 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Mar 02 2004 | 12 years fee payment window open |
| Sep 02 2004 | 6 months grace period start (w surcharge) |
| Mar 02 2005 | patent expiry (for year 12) |
| Mar 02 2007 | 2 years to revive unintentionally abandoned end. (for year 12) |